Miaoshun Biotechnology key facts
- Provider of cell and gene therapy platform intended to empower the innovative drug development industry.
- It has raised $28.2M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Addor Capital, GL Ventures, Zijin Hi-Tech Venture Capital, Nanjing Innovation Capital Group, Qingdao Haier Venture Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch Miaoshun Biotechnology: the Monday email on marks, rounds and moves
Miaoshun Biotechnology funding rounds
No funding rounds for Miaoshun Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Miaoshun Biotechnology investors
10 investors are on record for Miaoshun Biotechnology, including Addor Capital, GL Ventures, Zijin Hi-Tech Venture Capital and Nanjing Innovation Capital Group.
About Miaoshun Biotechnology
Provider of cell and gene therapy platform intended to empower the innovative drug development industry. The company's products and services include cell separation service platforms, cell culture platforms and drug discovery platforms, permitting clients to enhance innovative drug discovery and development capabilities.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2014
- Employees
- 10
- Website
- miles-bio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Miaoshun Biotechnology doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.